View ValuationDynamic solutionLtd 将来の成長Future 基準チェック /06現在、 Dynamic solutionLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長45.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).分析記事 • Jan 11Some Shareholders Feeling Restless Over Neofect Co., Ltd.'s (KOSDAQ:290660) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Medical Equipment industry in Korea, you could be...New Risk • Jan 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩51.6b market cap, or US$35.7m).New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩44.4b market cap, or US$30.8m).お知らせ • Nov 28Neofect Co., Ltd. announced that it has received KRW 5.49999938 billion in funding from Yeomi Midia Co. Ltd.,On November 27, 2025. Neofect Co., Ltd. announced that it has closed the transaction.お知らせ • Oct 14Neofect Co., Ltd. announced that it has received KRW 1 billion in funding from Organ Eco Tech Co.,Ltd.On October 13, 2025, Neofect Co., Ltd. closed the transaction.分析記事 • Sep 28Some Confidence Is Lacking In Neofect Co., Ltd. (KOSDAQ:290660) As Shares Slide 26%To the annoyance of some shareholders, Neofect Co., Ltd. ( KOSDAQ:290660 ) shares are down a considerable 26% in the...お知らせ • Aug 21Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660).Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025. As of August 19, 2025, the deal is expected to complete on August 19, 2025. Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) on August 19, 2025.Reported Earnings • Aug 14Second quarter 2025 earnings released: ₩327 loss per share (vs ₩82.00 profit in 2Q 2024)Second quarter 2025 results: ₩327 loss per share (down from ₩82.00 profit in 2Q 2024). Revenue: ₩6.20b (up 15% from 2Q 2024). Net loss: ₩15.1b (down ₩18.5b from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Aug 13Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others.Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund agreed to acquire 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others for KRW 27 billion on June 27, 2025. A cash consideration of KRW 27 billion valued at KRW 2000 per share will be paid by Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund for 13.5 million shares of Neofect Co., Ltd. As part of consideration, KRW 27 billion is paid towards common equity of Neofect Co., Ltd. Post the transaction, Scandi New Technology Association No. 278 will hold 3.16% stake in Neofect Co., Ltd. The expected completion of the transaction is August 13, 2025. Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others on August 12, 2025.分析記事 • Jul 30Revenues Not Telling The Story For Neofect Co., Ltd. (KOSDAQ:290660)When you see that almost half of the companies in the Medical Equipment industry in Korea have price-to-sales ratios...お知らせ • Jul 29Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion.Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025.New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩65.2b market cap, or US$47.2m).お知らせ • Jun 20Neofect Co., Ltd. announced that it expects to receive KRW 12 billion in fundingNeofect Co., Ltd announced a private placement to issue 7,500,000 shares at an issue price of KRW 800 per share for gross proceeds of KRW 6,000,000,000 on June 18, 2025. The transaction will include participation from new investor Fleur New Technology Fund No. 91. The transaction has been approved by shareholders, restricted to a hold period, expected to close on August 18, 2025. 7,500,000 shares - The company will issue 7,500,000 shares at an issue price of KRW 800 per share gross proceeds of KRW 6,000,000,000; aggregate gross proceeds of KRW 12,000,000,000. The transaction will include participation from new investor Sion New Technology Fund No. 90. The transaction has been approved by shareholders, restricted to a hold period, expected to close on July 18, 2025.New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩54.4b market cap, or US$39.6m).お知らせ • Mar 14Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (35% increase in shares outstanding). Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).分析記事 • Dec 04Investor Optimism Abounds Neofect Co., Ltd. (KOSDAQ:290660) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...お知らせ • Oct 22Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million.Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,145,475 Price\Range: KRW 873 Transaction Features: Subsequent Direct Listingお知らせ • Oct 17Neofect Co., Ltd. announced that it expects to receive KRW 1.99999935 billion in funding from Aprogen I&C, Inc.Neofect Co., Ltd. announced a private placement to issue 2,290,950 common shares at an issue price of KRW 873 per share for the gross proceeds of KRW 1,999,999,350 on October 15, 2024. The transaction will include participation from new investor Aprogen I&C, Inc. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 23, 2024.お知らせ • Oct 09Neofect Co., Ltd. announced that it expects to receive KRW 999.999675 million in funding from Cj Consulting Co., Ltd., YR Invest Co., LtdNeofect Co., Ltd. announced a private placemen to issue 1,145,475 shares at an issue price of KRW 873 per share for the gross proceeds of KRW 999,999,675 on October 8, 2024. The transaction will include participation from new investors Cj Consulting Co., Ltd. 916,380 shares and YR Invest Co., Ltd 229,095 shares. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 21, 2024.分析記事 • Jun 19There Is A Reason Neofect Co.,Ltd's (KOSDAQ:290660) Price Is UndemandingWith a price-to-sales (or "P/S") ratio of 1.6x Neofect Co.,Ltd ( KOSDAQ:290660 ) may be sending bullish signals at the...お知らせ • Apr 10Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Scandi New Technology Association No. 278On April 9, 2024, Neofect Co.,Ltd. closed the transaction. The company issued 2,722,323 common shares at an issue price of KRW 1,102 for the gross proceeds of KRW 2,999,999,946 in its second and final tranche closing. The company has received KRW 4,999,999,910 in the transaction.お知らせ • Dec 28Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Kyowon Life, Inc., Scandi New Technology Association No. 278On December 26, 2023, Neofect Co.,Ltd. closed the transaction. The company received KRW 1,999,999,964 in its second and final tranche closing.New Risk • Nov 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.0b market cap, or US$28.7m).New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩35.6b market cap, or US$27.3m).お知らせ • Jan 17Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 692,041 Price\Range: KRW 1445 Transaction Features: Subsequent Direct Listing分析記事 • Mar 17NeofectLtd's (KOSDAQ:290660) Stock Price Has Reduced 19% In The Past YearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...Is New 90 Day High Low • Feb 24New 90-day low: ₩3,015The company is down 16% from its price of ₩3,570 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period.Is New 90 Day High Low • Feb 03New 90-day low: ₩3,105The company is down 19% from its price of ₩3,810 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩3,215The company is down 16% from its price of ₩3,815 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period.Is New 90 Day High Low • Dec 28New 90-day low: ₩3,405The company is down 25% from its price of ₩4,545 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: ₩3,510The company is down 10.0% from its price of ₩3,905 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period.Reported Earnings • Dec 06Third quarter 2020 earnings released: ₩309 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: ₩4.35b (down 15% from 3Q 2019). Net loss: ₩3.80b (loss widened 7.6% from 3Q 2019).お知らせ • Nov 12Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,500,000 Price\Range: KRW 2860 Discount Per Security: KRW 64.35 Transaction Features: ESOP Related Offering; Rights OfferingIs New 90 Day High Low • Oct 26New 90-day low: ₩3,540The company is down 29% from its price of ₩5,020 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Dynamic solutionLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A290660 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202516,053-10,803-2,327-233N/A9/30/202520,498-16,845-1,205308N/A6/30/202520,685-20,1402,2742,571N/A3/31/202521,111-1,644-842-536N/A12/31/202417,275-1,902-1,446-1,136N/A9/30/202418,694-4,621-5,499-4,924N/A6/30/202421,878-1,512-6,635-6,290N/A3/31/202424,918-4,863-4,241-3,699N/A12/31/202326,614-4,963-4,852-4,353N/A9/30/202328,269-5,356-2,330-2,163N/A6/30/202326,529-7,692-4,729-4,381N/A3/31/202325,967-9,137-6,020-5,727N/A12/31/202226,202-9,621-6,095-5,702N/A9/30/202225,557-3,996-4,475-3,820N/A6/30/202225,550-3,204-5,287-4,118N/A3/31/202224,421-4,844-6,271-4,731N/A12/31/202123,158-5,045-6,388-4,840N/A9/30/202120,340-9,269-7,688-6,112N/A6/30/202119,696-11,466-8,109-6,907N/A3/31/202119,064-13,398-7,273-7,056N/A12/31/202018,625-15,007-10,002-9,061N/A9/30/202017,726-20,617-13,095-11,595N/A6/30/202018,477-20,348-17,100-12,668N/A3/31/202015,551-17,963-20,727-15,536N/A12/31/201912,311-15,845-23,462-13,920N/A9/30/201911,099-9,704N/A-13,275N/A6/30/20197,071-8,088N/A-11,908N/A3/31/20196,583-9,517N/A-8,978N/A12/31/20185,653-9,634N/A-8,184N/A9/30/20184,527-9,181N/A-6,584N/A6/30/20184,882-8,276N/A-5,627N/A3/31/20184,234-5,190N/A-6,259N/A12/31/20174,454-4,389N/A-7,175N/A12/31/20161,980-5,920N/A-4,924N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A290660の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A290660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A290660の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A290660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A290660の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A290660の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 16:25終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dynamic solution Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.
お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.
Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).
分析記事 • Jan 11Some Shareholders Feeling Restless Over Neofect Co., Ltd.'s (KOSDAQ:290660) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Medical Equipment industry in Korea, you could be...
New Risk • Jan 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩51.6b market cap, or US$35.7m).
New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩44.4b market cap, or US$30.8m).
お知らせ • Nov 28Neofect Co., Ltd. announced that it has received KRW 5.49999938 billion in funding from Yeomi Midia Co. Ltd.,On November 27, 2025. Neofect Co., Ltd. announced that it has closed the transaction.
お知らせ • Oct 14Neofect Co., Ltd. announced that it has received KRW 1 billion in funding from Organ Eco Tech Co.,Ltd.On October 13, 2025, Neofect Co., Ltd. closed the transaction.
分析記事 • Sep 28Some Confidence Is Lacking In Neofect Co., Ltd. (KOSDAQ:290660) As Shares Slide 26%To the annoyance of some shareholders, Neofect Co., Ltd. ( KOSDAQ:290660 ) shares are down a considerable 26% in the...
お知らせ • Aug 21Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660).Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025. As of August 19, 2025, the deal is expected to complete on August 19, 2025. Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) on August 19, 2025.
Reported Earnings • Aug 14Second quarter 2025 earnings released: ₩327 loss per share (vs ₩82.00 profit in 2Q 2024)Second quarter 2025 results: ₩327 loss per share (down from ₩82.00 profit in 2Q 2024). Revenue: ₩6.20b (up 15% from 2Q 2024). Net loss: ₩15.1b (down ₩18.5b from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Aug 13Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others.Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund agreed to acquire 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others for KRW 27 billion on June 27, 2025. A cash consideration of KRW 27 billion valued at KRW 2000 per share will be paid by Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund for 13.5 million shares of Neofect Co., Ltd. As part of consideration, KRW 27 billion is paid towards common equity of Neofect Co., Ltd. Post the transaction, Scandi New Technology Association No. 278 will hold 3.16% stake in Neofect Co., Ltd. The expected completion of the transaction is August 13, 2025. Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others on August 12, 2025.
分析記事 • Jul 30Revenues Not Telling The Story For Neofect Co., Ltd. (KOSDAQ:290660)When you see that almost half of the companies in the Medical Equipment industry in Korea have price-to-sales ratios...
お知らせ • Jul 29Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion.Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025.
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩65.2b market cap, or US$47.2m).
お知らせ • Jun 20Neofect Co., Ltd. announced that it expects to receive KRW 12 billion in fundingNeofect Co., Ltd announced a private placement to issue 7,500,000 shares at an issue price of KRW 800 per share for gross proceeds of KRW 6,000,000,000 on June 18, 2025. The transaction will include participation from new investor Fleur New Technology Fund No. 91. The transaction has been approved by shareholders, restricted to a hold period, expected to close on August 18, 2025. 7,500,000 shares - The company will issue 7,500,000 shares at an issue price of KRW 800 per share gross proceeds of KRW 6,000,000,000; aggregate gross proceeds of KRW 12,000,000,000. The transaction will include participation from new investor Sion New Technology Fund No. 90. The transaction has been approved by shareholders, restricted to a hold period, expected to close on July 18, 2025.
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩54.4b market cap, or US$39.6m).
お知らせ • Mar 14Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (35% increase in shares outstanding). Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).
分析記事 • Dec 04Investor Optimism Abounds Neofect Co., Ltd. (KOSDAQ:290660) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...
お知らせ • Oct 22Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million.Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,145,475 Price\Range: KRW 873 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 17Neofect Co., Ltd. announced that it expects to receive KRW 1.99999935 billion in funding from Aprogen I&C, Inc.Neofect Co., Ltd. announced a private placement to issue 2,290,950 common shares at an issue price of KRW 873 per share for the gross proceeds of KRW 1,999,999,350 on October 15, 2024. The transaction will include participation from new investor Aprogen I&C, Inc. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 23, 2024.
お知らせ • Oct 09Neofect Co., Ltd. announced that it expects to receive KRW 999.999675 million in funding from Cj Consulting Co., Ltd., YR Invest Co., LtdNeofect Co., Ltd. announced a private placemen to issue 1,145,475 shares at an issue price of KRW 873 per share for the gross proceeds of KRW 999,999,675 on October 8, 2024. The transaction will include participation from new investors Cj Consulting Co., Ltd. 916,380 shares and YR Invest Co., Ltd 229,095 shares. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 21, 2024.
分析記事 • Jun 19There Is A Reason Neofect Co.,Ltd's (KOSDAQ:290660) Price Is UndemandingWith a price-to-sales (or "P/S") ratio of 1.6x Neofect Co.,Ltd ( KOSDAQ:290660 ) may be sending bullish signals at the...
お知らせ • Apr 10Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Scandi New Technology Association No. 278On April 9, 2024, Neofect Co.,Ltd. closed the transaction. The company issued 2,722,323 common shares at an issue price of KRW 1,102 for the gross proceeds of KRW 2,999,999,946 in its second and final tranche closing. The company has received KRW 4,999,999,910 in the transaction.
お知らせ • Dec 28Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Kyowon Life, Inc., Scandi New Technology Association No. 278On December 26, 2023, Neofect Co.,Ltd. closed the transaction. The company received KRW 1,999,999,964 in its second and final tranche closing.
New Risk • Nov 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.0b market cap, or US$28.7m).
New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩35.6b market cap, or US$27.3m).
お知らせ • Jan 17Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 692,041 Price\Range: KRW 1445 Transaction Features: Subsequent Direct Listing
分析記事 • Mar 17NeofectLtd's (KOSDAQ:290660) Stock Price Has Reduced 19% In The Past YearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Is New 90 Day High Low • Feb 24New 90-day low: ₩3,015The company is down 16% from its price of ₩3,570 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Feb 03New 90-day low: ₩3,105The company is down 19% from its price of ₩3,810 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩3,215The company is down 16% from its price of ₩3,815 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Dec 28New 90-day low: ₩3,405The company is down 25% from its price of ₩4,545 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: ₩3,510The company is down 10.0% from its price of ₩3,905 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period.
Reported Earnings • Dec 06Third quarter 2020 earnings released: ₩309 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: ₩4.35b (down 15% from 3Q 2019). Net loss: ₩3.80b (loss widened 7.6% from 3Q 2019).
お知らせ • Nov 12Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,500,000 Price\Range: KRW 2860 Discount Per Security: KRW 64.35 Transaction Features: ESOP Related Offering; Rights Offering
Is New 90 Day High Low • Oct 26New 90-day low: ₩3,540The company is down 29% from its price of ₩5,020 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.